Compare Natera Inc. Common Stock (NTRA) vs Primo Brands Corporation Class A Common Stock (PRMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Primo Brands Corporation Class A Common Stock — how do they compare? Natera Inc. Common Stock trades at $392.22 (market cap $57.03B), while Primo Brands Corporation Class A Common Stock trades at $18.76 (market cap $6.84B). The key difference: Natera Inc. Common Stock is far larger — about 8.3× Primo Brands Corporation Class A Common Stock's market cap, and Primo Brands Corporation Class A Common Stock pays a 2.54% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Primo Brands Corporation Class A Common Stock for 0 Days on average.
| NTRA | PRMB | |
|---|---|---|
Market Cap | $57.03B | $6.84B |
Volume | 1,131,157 | 2,864,594 |
Sector | Health | Consumer Staples |
52-Week High | $425.64 | $25.39 |
52-Week Low | $179.42 | $14.46 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $56.18B | $12.17B |
Dividend Yield | — | 2.54% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
PRMB trades at $18.9, down 1.46% on the day, with a neutral technical signal and key support/resistance clustered around $19. The company reported Q2 2026 EPS of $0.37, beating expectations, and shows improving revenue and net income trends for 2026. Recent news highlights expansion with a new factory opening and strong premium water sales growth, supporting a positive analyst consensus.
The outlook is positive, driven by sales momentum and capacity expansion, but risks include thin net margins and high P/E ratio. With 80% of analysts rating it Buy and a consensus price target of $28.50, the stock offers significant upside potential if execution continues, though margin pressure remains a key watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Primo Brands Corporation Class A Common Stock
Primo Brands Corporation is a branded beverage company that produces and distributes packaged and purified water, water dispensers, and filtration equipment across North America, under brands including Poland Spring, Pure Life, Arrowhead, and Primo Water.
Read more on PRMB →
